Akèy › Kansè (tout kalite) › Kalifòni › Mountain View
Etid klinik pou Kansè (tout kalite) nan Mountain View, CA
40 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Stanford University School of Medicine, Stanford · 5 mi lwen
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Stanford University, Palo Alto · 5 mi lwen
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 5, Stanford · 5 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Sutter Palo Alto Medical Foundation: Palo Alto, Palo Alto · 5 mi lwen
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Ap rekriteFaz 2/3
- Stanford Cancer Center, Stanford · 5 mi lwen
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Ap rekriteFaz 1
- Investigational Site Number: 403, Palo Alto · 5 mi lwen
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Palo Alto · 5 mi lwen
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- Stanford, Palo Alto · 5 mi lwen
Prostate Active Surveillance Study
Ap rekriteEtid obsèvasyon
- Stanford University, Stanford · 5 mi lwen
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Stanford University, Palo Alto · 5 mi lwen
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 5 mi lwen
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford University, Palo Alto · 5 mi lwen
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- Stanford Cancer Center, Palo Alto · 5 mi lwen
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
- ak 1 plis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 150, Palo Alto · 5 mi lwen
Evaluation of Grief Therapy Approaches for Bereaved Parents
Ap rekrite
- Stanford University (Data Collection Only), Stanford · 5 mi lwen
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Stanford University - Stanford Cancer Institute, Stanford · 5 mi lwen
Childhood Cancer Survivor Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Stanford University School of Medicine, Stanford · 5 mi lwen
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Ap rekrite
- VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto · 5 mi lwen
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Stanford University, Stanford · 5 mi lwen
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
Galleri® in the Medicare Population.
Ap rekriteVolontè an sante akeyi
- Sutter Valley Hospitals PAMF Sutter, Palo Alto · 5 mi lwen
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Ap rekriteFaz 1
- GSK Investigational Site, Stanford · 5 mi lwen
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Ap rekriteFaz 1/2
- Lucille Packard Children's Hospital Stanford, Palo Alto · 5 mi lwen
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Impact of the Coronavirus (COVID-19) on Patients With Cancer
Ap rekriteEtid obsèvasyon
- Stanford University School of Medicine, Stanford · 5 mi lwen
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Ap rekriteFaz 2
- Byers Eye Institute at Stanford University, Palo Alto · 5 mi lwen
Engagement of Veterans With Lung Cancer
Ap rekrite
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5 mi lwen
Adolescents and Young Adults With Cancer: Their Preferred Involvement in Decision Making
Ap rekriteVolontè an sante akeyi
- Stanford University, Palo Alto · 5 mi lwen
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Stanford University School of Medicine, Stanford · 5 mi lwen
Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer
Ap rekrite
- Stanford University, Palo Alto · 5 mi lwen
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Ap rekriteFaz 1
- Stanford Cancer Institute, Palo Alto · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Stanford · 5 mi lwen
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
Ap rekriteEtid obsèvasyon
- Stanford Cancer Center, Palo Alto · 5 mi lwen
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Exai Bio Inc., Palo Alto · 5 mi lwen
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Ap rekrite
- Stanford Cancer Institute, Palo Alto · 5 mi lwen
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
Ap rekriteFaz 1/2
- Stanford University Cancer Institute, Stanford · 5 mi lwen
xPedite: A Study to Expedite DIPG and DMG Research
Ap rekriteEtid obsèvasyon
- xCures, Inc., Los Altos · 2 mi lwen
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY110 etid
- Boston, MA86 etid
- Los Angeles, CA73 etid
- Nashville, TN65 etid
- Philadelphia, PA59 etid
- Durham, NC58 etid
- Washington, DC58 etid
- Chicago, IL51 etid
- Seattle, WA49 etid
- Atlanta, GA49 etid
- Arlington, VA48 etid
Lòt etid nan Mountain View
- Kansè nan tete25 etid
- Kansè Metastatik25 etid
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi19 etid
- Kansè ovè19 etid
- Twoub Spektòm Otis17 etid
- Kansè poumon17 etid
- Ensifizyans kadyak15 etid
- Kansè pwostat15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
- Kansè kolorektal13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.